A5027330233- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer therapeutics and mechanisms
- Animal Virus Infections Studies
- Virus-based gene therapy research
- Viral gastroenteritis research and epidemiology
- Receptor Mechanisms and Signaling
- Estrogen and related hormone effects
- Radiopharmaceutical Chemistry and Applications
- interferon and immune responses
- Advanced Nanomaterials in Catalysis
- Extracellular vesicles in disease
- Nanoplatforms for cancer theranostics
- Pharmacological Effects of Medicinal Plants
- Saffron Plant Research Studies
- Nanoparticle-Based Drug Delivery
- Plant Virus Research Studies
Huazhong Agricultural University
2023-2024
Center of Hubei Cooperative Innovation for Emissions Trading System
2023-2024
China Pharmaceutical University
2024
State Key Laboratory of Natural Medicine
2024
Zymeworks (Canada)
2018-2024
Jiangxi Agricultural University
2020
Jilin Agricultural University
2018
Chinese Academy of Medical Sciences & Peking Union Medical College
2018
Gorgias Press (United States)
2015
Institute of Electrical and Electronics Engineers
2015
Abstract In recent years, the field of antibody drug conjugates (ADC) has seen a resurgence, largely driven by clinical benefit observed in patients treated with ADCs incorporating camptothecin-based topoisomerase I inhibitor payloads. Herein, we present development novel camptothecin ZD06519 (FD1), which been specifically designed for its application as an ADC payload. A panel analogs different substituents at C-7 and C-10 positions core was prepared tested vitro. Selected compounds...
Abstract Background: HER2-targeted therapies have transformed the treatment of patients with HER2-expressing breast and gastric cancers. Despite this, there remains a need for new treatments that are well tolerated effective not only cancers high HER2 expression levels but also those lower expression. ZW49 is an antibody drug conjugate (ADC) combines novel auristatin payload (potent anti-cancer agent) unique mechanisms action anti-HER2 biparatopic antibody, ZW25, which binds to same domains...
G-quadruplex (G4) is a unique secondary structure formed by guanine-rich nucleic acid sequences. Growing studies reported that the genomes of some viruses harbor G4 structures associated with viral replication, opening up new field to dissect infection. Porcine reproductive and respiratory syndrome virus (PRRSV), representative member Arteriviridae, an economically significant pathogen has devastated swine industry worldwide for over 30 years. In this study, we identified highly conserved...
Porcine epidemic diarrhea virus (PEDV) is a reemerging enteropathogenic coronavirus that causes high mortality in piglets and has catastrophic effects on the global pig industry. PEDV-encoded nonstructural protein 7 (nsp7) an important component of viral replication transcription complex, previous study reported it inhibits poly(I:C)-induced type I interferon (IFN) production, but mechanism by which this occurs remains unclear. Here, we demonstrated ectopic expression PEDV nsp7 antagonized...
Abstract Therapies targeting HER2 have transformed the treatment of patients with HER2-expressing breast and gastric cancers. Unfortunately, many recur following HER2-targeted treatments new therapies are needed. Multiple antibody-drug conjugate (ADC) technologies being explored in this setting, some which utilize anti-HER2 antibody trastuzumab. Here we present preclinical characterization a biparatopic ADC, ZW49, is generated from conjugation novel N-acyl sulfonamide auristatin payload to...
Retrograde transport has been reported to be closely associated with normal cellular biological processes and viral replication. As an emerging enteropathogenic coronavirus zoonotic potential, porcine deltacoronavirus (PDCoV) attracted considerable attention. However, whether retrograde is PDCoV infection remains unclear. Our present study demonstrates that retromer protein VPS35 acts as a critical host factor required for infection. Mechanically, interacts NS6, mediating the of NS6 from...
<p>Supplementary Figure S2 shows the chemical stability of FD1 (ZD06519)</p>
<p>Supplementary Figure S3 shows the in vitro cytotoxicity assessment of trastuzumab-ADCs both two-dimensional (2D) and three-dimensional (3D) spheroid assays</p>
<p>Synthesis and characterization of free drugs drug-linkers</p>
<p>Supplementary Figure S4 shows the pharmacokinetic analysis of ADCs (total antibody PK) from tolerability study in rats</p>
<p>Supplementary Figure S4 shows the pharmacokinetic analysis of ADCs (total antibody PK) from tolerability study in rats</p>
<p>Synthesis and characterization of free drugs drug-linkers</p>
<p>HPLC-HIC, LC-MS, HPLC-SEC, residual free drug analysis, and endotoxin levels of ADCs</p>
<div>Abstract<p>In recent years, the field of antibody drug conjugates (ADC) has seen a resurgence, largely driven by clinical benefit observed in patients treated with ADCs incorporating camptothecin-based topoisomerase I inhibitor payloads. Herein, we present development novel camptothecin ZD06519 (FD1), which been specifically designed for its application as an ADC payload. A panel analogs different substituents at C-7 and C-10 positions core was prepared tested <i>in...
<p>Supplementary Figure S3 shows the in vitro cytotoxicity assessment of trastuzumab-ADCs both two-dimensional (2D) and three-dimensional (3D) spheroid assays</p>
<p>Supplementary Figure S1 shows the murine plasma stability of T-DL4 and T-DL13</p>
<p>Supplementary Figure S1 shows the murine plasma stability of T-DL4 and T-DL13</p>